ACTG1P17

Across TCGA pan-cancer cohorts, ACTG1P17 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated ACTG1P17 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ACTG1P17 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTG1P17 expression acts as an unfavorable survival marker, although some lineages such as CESC and BLCA show a favorable association.

KIRC, COAD, and UVM are the cancer types where ACTG1P17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.529	0.695	<.001	125	view →
COAD	OS	Tertile	All	0.835	0.935	<.001	74	view →
UVM	DFS	Median	III,IV	0.238	0.720	.001	59	view →
CESC	OS	Tertile	All	0.674	0.459	.001	58	view →
BLCA	OS	Tertile	II,III,IV	0.702	0.530	.002	53	view →
LGG	DFS	Quartile	All	0.740	0.862	<.001	22	view →
MESO	DFS	Median	IV	0.182	0.450	.011	20	view →
PAAD	OS	Quartile	All	0.593	0.211	.006	19	view →
LIHC	DFS	Median	All	0.201	0.400	.004	14	view →
PRAD	DFS	Median	All	0.838	0.930	<.001	14	view →
CHOL	DFS	Tertile	All	0.770	0.183	.002	12	view →
HNSC	DFS	Median	IV	0.705	0.581	.007	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

ACTG1P17–KIRC (DFS)

Open the KIRC breakdown →